A5247
A
Phase II, Randomized, Double-Blind, Placebo-Controlled
Clinical Trial to Evaluate the Safety, Tolerability,
and Immunogenicity of ZOSTAVAX® (Zoster Vaccine
Live) in Human Immunodeficiency Virus (HIV)-1-Infected
Adults on Potent Combination ART with Conserved Immune
Function..
Purpose of this Study: This study
will determine how well ZOSTAVAX is tolerated by HIV-1-infected
adults with healthy immune systems who are on antiretroviral
therapy and also to determine how effective the vaccine
is in the development of protection against reactivation
of the varicella virus..
Requirements to Enter Study:
- You must be 18 years of age or older
- On antiretroviral therapy
- CD4 count > 350 for Stage I or >
200 for Stage II.
- You can not have previously received a vaccine
for chickenpox or herpes zoster.
Treatment: You will receive a
vaccine or placebo injection at study entry and at
week 6.
Duration of Study: You will be
on study for up to 12-14 weeks
For
more information contact:
Study
Contacts
Joseph
Quinn, RN (215) 349-8092
